{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:03:55Z","timestamp":1792821835818,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejmech.2024.116731","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:14:07Z","timestamp":1722590047000},"page":"116731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications"],"prefix":"10.1016","volume":"277","author":[{"given":"Yao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116731_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152706784111614","article-title":"Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia","volume":"5","author":"Werkman","year":"2006","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.ejmech.2024.116731_bib4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1590\/s0104-59702021000300003","article-title":"On the so-called psychopharmacological revolution: the discovery of chlorpromazine and the management of madness","volume":"28","author":"Caponi","year":"2021","journal-title":"Hist\u00f3ria, Ci\u00eancias, Sa\u00fade-Manguinhos"},{"key":"10.1016\/j.ejmech.2024.116731_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0010-440X(64)80031-6","article-title":"The butyrophenones in the treatment of the psychotic patient","volume":"5","author":"Kurland","year":"1964","journal-title":"Compr. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.116731_bib6","first-page":"67","article-title":"Aripiprazole: an overview of a novel antipsychotic","volume":"17","author":"Uzun","year":"2005","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.ejmech.2024.116731_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2015.02.025","article-title":"Dopamine receptor partial agonists and addiction","volume":"752","author":"Moreira","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.euroneuro.2013.06.005","article-title":"Schizophrenia and dopamine receptors","volume":"23","author":"Seeman","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejmech.2024.116731_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S1461145713001296","article-title":"Gender-specific association of the SLC6A4 and DRD2 gene variants in bipolar disorder","volume":"17","author":"Wang","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1039856219839476","article-title":"Dopamine dysregulation syndrome in non-Parkinson's disease patients: a systematic review","volume":"27","author":"Cartoon","year":"2019","journal-title":"Australas. Psychiatr.: bulletin of Royal Australian and New Zealand College of Psychiatrists"},{"key":"10.1016\/j.ejmech.2024.116731_bib11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: from receptor-binding profiles to metabolic side effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacology & therapeutics"},{"key":"10.1016\/j.ejmech.2024.116731_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","article-title":"Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects","volume":"41","author":"Rognoni","year":"2021","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejmech.2024.116731_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116731_bib15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2174\/1381612043384088","article-title":"Side effects of atypical antipsychotic drugs","volume":"10","author":"Ananth","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2024.116731_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1013205230142","article-title":"The neurobiology of dopamine signaling","volume":"21","author":"Greengard","year":"2001","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2024.116731_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/RRS-200029981","article-title":"Dopamine receptor signaling","volume":"24","author":"Neve","year":"2004","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.ejmech.2024.116731_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors-IUPHAR review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature11466","article-title":"Dopaminergic neurons inhibit striatal output through non-canonical release of GABA","volume":"490","author":"Tritsch","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116731_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends in neurosciences"},{"key":"10.1016\/j.ejmech.2024.116731_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211034019","article-title":"The role of lumateperone in the treatment of schizophrenia","volume":"11","author":"Syed","year":"2021","journal-title":"Therapeutic advances in psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.116731_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1358\/dot.2018.54.12.2899443","article-title":"Lumateperone: a new treatment approach for neuropsychiatric disorders","volume":"54","author":"Kumar","year":"2018","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2024.116731_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.ejmech.2024.116731_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","article-title":"Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials","volume":"36","author":"Kane","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib26","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm401958n","article-title":"Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116731_bib27","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s40265-017-0848-4","article-title":"Aripiprazole lauroxil: a review in schizophrenia","volume":"77","author":"Frampton","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/neurolint13030029","article-title":"Aripiprazole lauroxil, a novel injectable long-acting antipsychotic treatment for adults with schizophrenia: a comprehensive review","volume":"13","author":"Maini","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.ejmech.2024.116731_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3371\/csrp.AGGA.040316","article-title":"Aripiprazole lauroxil long-acting injectable: the latest addition to second-generation long-acting agents","volume":"10","author":"Aggarwal","year":"2016","journal-title":"Clin. Schizophrenia Relat. Psychoses"},{"key":"10.1016\/j.ejmech.2024.116731_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/14737175.2024.2313550","article-title":"Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults","volume":"24","author":"Samalin","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2024.116731_bib31","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/jm940608g","article-title":"Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives","volume":"41","author":"Oshiro","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116731_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40263-017-0442-z","article-title":"Cariprazine: a review in schizophrenia","volume":"31","author":"Garnock-Jones","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17460441.2018.1471057","article-title":"The preclinical discovery and development of cariprazine for the treatment of schizophrenia","volume":"13","author":"Weso\u0142owska","year":"2018","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12325-013-0006-7","article-title":"Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2024.116731_bib35","series-title":"3-cyclohexyl-1,1-dimethylurea Compound as Well as Preparation Method and Application Thereof","author":"Li","year":"2015"},{"key":"10.1016\/j.ejmech.2024.116731_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-019-1052-5","article-title":"Brexpiprazole: a review in schizophrenia","volume":"79","author":"Frampton","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14656566.2016.1274972","article-title":"Brexpiprazole for the treatment of schizophrenia","volume":"18","author":"Hsu","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/17460441.2017.1354849","article-title":"The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder","volume":"12","author":"Aftab","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib39","first-page":"1","article-title":"An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents","volume":"5","author":"Crump","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2024.116731_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophrenia research"},{"key":"10.1016\/j.ejmech.2024.116731_bib41","series-title":"Method for Producing Benzo[b]thiophene Compound","author":"Shinhama","year":"2013"},{"key":"10.1016\/j.ejmech.2024.116731_bib42","article-title":"Loxapine for schizophrenia","volume":"4","author":"Fenton","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003495-197815030-00002","article-title":"Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent","volume":"15","author":"Heel","year":"1978","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib44","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2147\/NDT.S173567","article-title":"Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults","volume":"15","author":"Faden","year":"2019","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejmech.2024.116731_bib45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2024.116731_bib46","series-title":"Preparation Method of Loxapine and Key Intermediate of Loxapine","author":"Zhai","year":"2014"},{"key":"10.1016\/j.ejmech.2024.116731_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116731_bib48","article-title":"Lurasidone for treating schizophrenia and bipolar depression: a review of its efficacy","volume":"15","author":"Tarzian","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2024.116731_bib49","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.2147\/DDDT.S366769","article-title":"Lurasidone for the treatment of schizophrenia: design, development, and place in therapy","volume":"17","author":"Miura","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2024.116731_bib50","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1517\/17460441.2013.815163","article-title":"The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia","volume":"8","author":"Tarazi","year":"2013","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2024.116731_bib52","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/cap.2021.0040","article-title":"Tolerability, safety, and effectiveness of two years of treatment with lurasidone in children and adolescents with bipolar depression","volume":"31","author":"DelBello","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib53","series-title":"Intermediate Compounds and Process for the Preparation of Lurasidone and Salts Thereof","author":"Maron","year":"2013"},{"key":"10.1016\/j.ejmech.2024.116731_bib54","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/14656566.2019.1617849","article-title":"Asenapine for the treatment of bipolar disorder","volume":"20","author":"Marazziti","year":"2019","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2147\/PPA.S235104","article-title":"Transdermal asenapine in schizophrenia: a systematic review","volume":"14","author":"Carrithers","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ejmech.2024.116731_bib56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40263-016-0363-2","article-title":"Asenapine: a review in schizophrenia","volume":"30","author":"Plosker","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.24869\/psyd.2019.157","article-title":"Asenapine: pharmacological aspects and role in psychiatric disorders","volume":"31","author":"Reyad","year":"2019","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.ejmech.2024.116731_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1517\/17460441.2013.738193","article-title":"The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania","volume":"8","author":"Tarazi","year":"2013","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib59","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1517\/14656566.2010.506188","article-title":"Evaluation of the clinical efficacy of asenapine in schizophrenia","volume":"11","author":"Minassian","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib60","first-page":"803","article-title":"Asenapine review, part II: clinical efficacy, safety and tolerability","volume":"13","author":"Citrome","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2024.116731_bib61","series-title":"Process for the Preparation of Tetracyclic Derivatives and Intermediate Products Used in the Process","author":"Gorin","year":"2012"},{"key":"10.1016\/j.ejmech.2024.116731_bib62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1345\/aph.1M603","article-title":"Iloperidone for the treatment of schizophrenia","volume":"44","author":"Marino","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib63","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/10489070-000000000-00000","article-title":"Iloperidone: in schizophrenia","volume":"23","author":"Scott","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib64","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","article-title":"Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion","volume":"6","author":"Citrome","year":"2010","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.116731_bib65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1080\/14656566.2020.1798931","article-title":"An update on the efficacy and safety of iloperidone as a schizophrenia therapy","volume":"21","author":"Nair","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1092852912000764","article-title":"Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial","volume":"18","author":"Cutler","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejmech.2024.116731_bib67","series-title":"New Method for Preparing Iloperidone","author":"Ge","year":"2011"},{"key":"10.1016\/j.ejmech.2024.116731_bib68","article-title":"Paliperidone for schizophrenia","volume":"16","author":"Nussbaum","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib69","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2165\/0003495-200868160-00002","article-title":"Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability","volume":"68","author":"Bishara","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib70","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17460441.2020.1682994","article-title":"The preclinical discovery and development of paliperidone for the treatment of schizophrenia","volume":"15","author":"Weso\u0142owska","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib71","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1517\/14656566.2010.495387","article-title":"Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania","volume":"11","author":"Canuso","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2007.43.4.1067342","article-title":"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic","volume":"43","author":"Owen","year":"2007","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2024.116731_bib73","series-title":"Preparation Method of 3-(2-chloroethyl)-6, 7, 8, 9-Tetrahydro-9-Hydroxy-2-Methylenetetrahydrofolate-Pyrido [1,2-alpha] Pyrimidine-4-Ketone","author":"Li","year":"2010"},{"key":"10.1016\/j.ejmech.2024.116731_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1570163815666181008151718","article-title":"Aripiprazole: an FDA approved bioactive compound to treat schizophrenia- a mini review","volume":"17","author":"Kumar","year":"2020","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.ejmech.2024.116731_bib75","first-page":"1","article-title":"Efficacy and safety of aripiprazole in the treatment of delirium","author":"Jarosz","year":"2023","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.ejmech.2024.116731_bib76","article-title":"Aripiprazole for schizophrenia","volume":"19","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib77","first-page":"2635","article-title":"Aripiprazole: from pharmacological profile to clinical use","volume":"11","author":"Di Sciascio","year":"2015","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejmech.2024.116731_bib78","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1080\/14740338.2020.1832990","article-title":"A safety evaluation of aripiprazole in the treatment of schizophrenia","volume":"19","author":"Preda","year":"2020","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2024.116731_bib79","series-title":"A Novel Process for Preparation of Aripiprazole and its Intermediates","author":"Ramakrishnan","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116731_bib80","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1755-5949.2008.00056.x","article-title":"Ziprasidone in the treatment of affective disorders: a review","volume":"14","author":"Rosa","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejmech.2024.116731_bib81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0149-2918(02)85003-2","article-title":"Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia","volume":"24","author":"Stimmel","year":"2002","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116731_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00023210-200216090-00005","article-title":"Spotlight on ziprasidone in schizophrenia and schizoaffective disorder","volume":"16","author":"Gunasekara","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib83","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1517\/14656566.2010.507630","article-title":"Strategies for successful clinical management of schizophrenia with ziprasidone","volume":"11","author":"Fagiolini","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/cap.2021.0121","article-title":"Efficacy, safety, and tolerability of flexibly dosed ziprasidone in children and adolescents with mania in bipolar I disorder: a randomized placebo-controlled replication study","volume":"32","author":"Findling","year":"2022","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib85","series-title":"Controlled Synthesis of Ziprasidone and Compositions Thereof","author":"Busch","year":"2003"},{"key":"10.1016\/j.ejmech.2024.116731_bib86","article-title":"Quetiapine for schizophrenia","volume":"2004","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib87","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib88","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17460441.2017.1304378","article-title":"The preclinical discovery and development of quetiapine for the treatment of mania and depression","volume":"12","author":"Miranda","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neubiorev.2017.12.012","article-title":"The use of quetiapine in the treatment of major depressive disorder: Evidence from clinical and experimental studies","volume":"86","author":"Ign\u00e1cio","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"Suppl 13","key":"10.1016\/j.ejmech.2024.116731_bib90","first-page":"12","article-title":"Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia","volume":"63","author":"Nasrallah","year":"2002","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.ejmech.2024.116731_bib91","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/op900097q","article-title":"An improved and single pot process for the production of quetiapine hemifumarate substantially free from potential impurities","volume":"13","author":"Navnath","year":"2009","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2024.116731_bib92","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1586\/ern.11.75","article-title":"Pramipexole for the treatment of early Parkinson's disease","volume":"11","author":"Perez-Lloret","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2024.116731_bib93","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","article-title":"Role of pramipexole in the management of Parkinson's disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.116731_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1468-1331.2000.0070s1015.x","article-title":"Pre-clinical studies of pramipexole: clinical relevance","volume":"7","author":"Hubble","year":"2000","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejmech.2024.116731_bib95","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/ene.13303","article-title":"Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials","volume":"24","author":"Shen","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejmech.2024.116731_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(03)00217-X","article-title":"Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease","volume":"216","author":"Wong","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejmech.2024.116731_bib97","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.tetasy.2014.07.011","article-title":"Baker's yeast catalyzed preparation of a new enantiomerically pure synthon of (S)-pramipexole and its enantiomer (dexpramipexole)","volume":"25","author":"Ferraboschi","year":"2014","journal-title":"Tetrahedron: Asymmetry"},{"key":"10.1016\/j.ejmech.2024.116731_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001359","article-title":"Olanzapine for schizophrenia","volume":"2","author":"Duggan","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib99","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14656566.2011.553193","article-title":"Olanzapine pamoate for the treatment of schizophrenia","volume":"12","author":"Naber","year":"2011","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.116731_bib101","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS571>3.0.CO;2-5","article-title":"A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data","volume":"16","author":"Kennedy","year":"2001","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.116731_bib102","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4088\/JCP.v63n1210","article-title":"A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder","volume":"63","author":"Zajecka","year":"2002","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.ejmech.2024.116731_bib103","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1016\/j.tet.2010.08.022","article-title":"Bifunctional solid catalysts for chemoselective hydrogenation\u2013cyclisation\u2013amination cascade reactions of relevance for the synthesis of pharmaceuticals","volume":"66","author":"Leyva-P\u00e9rez","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2024.116731_bib104","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-200060010-00007","article-title":"Ropinirole: a review of its use in the management of Parkinson's disease","volume":"60","author":"Matheson","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib105","doi-asserted-by":"crossref","first-page":"o265","DOI":"10.1107\/S0108270106010535","article-title":"Ropinirole hydrochloride, a dopamine agonist, Acta crystallographica. Section C","volume":"62","author":"Ravikumar","year":"2006","journal-title":"Cryst. Struct. Commun."},{"key":"10.1016\/j.ejmech.2024.116731_bib106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1527-3458.2005.tb00046.x","article-title":"Ropinirole, a non-ergoline dopamine agonist","volume":"11","author":"Jost","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(91)90603-Y","article-title":"Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist","volume":"38","author":"Eden","year":"1991","journal-title":"Pharmacology, biochemistry, and behavior"},{"key":"10.1016\/j.ejmech.2024.116731_bib108","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1185\/030079906X132442","article-title":"Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme","volume":"22","author":"Giorgi","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2024.116731_bib109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","article-title":"Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials","volume":"33","author":"Kulisevsky","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2024.116731_bib110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/op400024a","article-title":"A new scalable route to 4-(2-Hydroxyethyl)-1,3-dihydro-2H-indol-2-one: a key intermediate for ropinirole hydrochloride","volume":"17","author":"Chen","year":"2013","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2024.116731_bib111","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1G378","article-title":"Risperidone treatment of bipolar mania","volume":"40","author":"Nguyen","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib112","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.6.5.803","article-title":"Risperidone: a review","volume":"6","author":"M\u00f6ller","year":"2005","journal-title":"Expet Opin. Pharmacother."},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2024.116731_bib113","first-page":"S80","article-title":"Pharmacological profile of risperidone, Canadian journal of psychiatry","volume":"38","author":"Ereshefsky","year":"1993","journal-title":"Rev. Canad. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.116731_bib114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/CIA.S3252","article-title":"Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia","volume":"4","author":"Singh","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejmech.2024.116731_bib115","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.clinthera.2004.12.009","article-title":"Clinical review of a long-acting, injectable formulation of risperidone","volume":"26","author":"Knox","year":"2004","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116731_bib116","first-page":"177","article-title":"Tolerability and safety profile of risperidone in a sample of children and adolescents","volume":"28","author":"Margari","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib117","series-title":"Method for Preparing Benzisoxazole Antipsychotic Drug Risperidone","author":"Zhao","year":"2015"},{"key":"10.1016\/j.ejmech.2024.116731_bib118","article-title":"Amisulpride for schizophrenia","volume":"2002","author":"Mota","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib119","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2165\/00003495-200161140-00014","article-title":"Amisulpride: a review of its use in the management of schizophrenia","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2024.116731_bib120","doi-asserted-by":"crossref","first-page":"s18","DOI":"10.1185\/030079902125001083","article-title":"Amisulpride: progress and outcomes","volume":"18","author":"Lecrubier","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2024.116731_bib121","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DHPS.S6226","article-title":"Safety and tolerability of antipsychotics: focus on amisulpride, Drug","volume":"2","author":"Juruena","year":"2010","journal-title":"healthcare and patient safety"},{"key":"10.1016\/j.ejmech.2024.116731_bib122","series-title":"Crystal Forms and Production Methods Thereof","author":"Snoonian","year":"2019"},{"key":"10.1016\/j.ejmech.2024.116731_bib123","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/MPG.0000000000003822","article-title":"Drugs in focus: domperidone","volume":"77","author":"Puoti","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ejmech.2024.116731_bib124","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1345\/aph.18003","article-title":"Domperidone: a peripherally acting dopamine2-receptor antagonist","volume":"33","author":"Barone","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116731_bib125","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/jim-2021-001968","article-title":"Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms","volume":"70","author":"Woods","year":"2022","journal-title":"J. Invest. Med.: the official publication of the American Federation for Clinical Research"},{"key":"10.1016\/j.ejmech.2024.116731_bib126","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPG.0000000000002409","article-title":"Safety and efficacy of low-dose domperidone for treating nausea and vomiting due to acute gastroenteritis in children","volume":"69","author":"Leitz","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ejmech.2024.116731_bib127","series-title":"Synthesis of Domperidone Maleate","author":"Li","year":"2006"},{"key":"10.1016\/j.ejmech.2024.116731_bib128","article-title":"Thioridazine for schizophrenia","volume":"2007","author":"Fenton","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2024.116731_bib129","first-page":"53","article-title":"Dopamine antagonism by thioridazine in schizophrenia","volume":"10","author":"Meltzer","year":"1975","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.116731_bib130","first-page":"535","article-title":"Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder","volume":"25","author":"Teicher","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ejmech.2024.116731_bib131","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jlcr.2580230708","article-title":"Synthesis of deuterium labelled thioridazine","volume":"23","author":"Mohammad","year":"1986","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2024.116731_bib132","volume":"2","year":"1971","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejmech.2024.116731_bib133","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1017\/S1478951514001059","article-title":"Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects","volume":"13","author":"Boettger","year":"2015","journal-title":"Palliat. Support Care"},{"key":"10.1016\/j.ejmech.2024.116731_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2019.09.017","article-title":"Efficacy and safety of haloperidol for delirium prevention in adult patients: an updated meta-analysis with trial sequential analysis of randomized controlled trials","volume":"61","author":"Chen","year":"2020","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.ejmech.2024.116731_bib135","doi-asserted-by":"crossref","first-page":"11353","DOI":"10.1021\/jacs.7b07078","article-title":"Direct aldehyde C-H arylation and alkylation via the combination of nickel, hydrogen atom transfer, and photoredox catalysis","volume":"139","author":"Zhang","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116731_bib136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cellsig.2017.07.003","article-title":"Advances and challenges in the search for D(2) and D(3) dopamine receptor-selective compounds","volume":"41","author":"Moritz","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2024.116731_bib137","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2024.116731_bib138","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0023210-200923010-00003","article-title":"Getting into the brain: approaches to enhance brain drug delivery","volume":"23","author":"Patel","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2024.116731_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-199600051-00003","article-title":"Extrapyramidal syndromes","volume":"5","author":"Casey","year":"1996","journal-title":"CNS Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2024.116731_bib140","first-page":"16","article-title":"Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality","volume":"61","author":"Glazer","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejmech.2024.116731_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","article-title":"Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia","volume":"41","author":"Grace","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2024.116731_bib142","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the \u03bc-opioid receptor-G(i) protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116731_bib143","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116731_bib144","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116731_bib145","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ejhg.2008.264","article-title":"Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis","volume":"17","author":"Need","year":"2009","journal-title":"European journal of human genetics"},{"key":"10.1016\/j.ejmech.2024.116731_bib146","series-title":"Schizophrenia: Recent Advances in Diagnosis and Treatment","first-page":"59","article-title":"Genetics of schizophrenia","author":"Sanders","year":"2014"},{"key":"10.1016\/j.ejmech.2024.116731_bib147","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejmech.2024.116731_bib148","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/026988110401800303","article-title":"Receptor mechanisms in the treatment of schizophrenia","volume":"18","author":"Reynolds","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116731_bib149","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A Deep learning approach to Antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116731_bib150","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:13:03Z","timestamp":1738411983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424006123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":150,"alternative-id":["S0223523424006123"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116731","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116731"}}